ES8600650A1 - Procedimiento para la preparacion de derivados de leucina - Google Patents

Procedimiento para la preparacion de derivados de leucina

Info

Publication number
ES8600650A1
ES8600650A1 ES533557A ES533557A ES8600650A1 ES 8600650 A1 ES8600650 A1 ES 8600650A1 ES 533557 A ES533557 A ES 533557A ES 533557 A ES533557 A ES 533557A ES 8600650 A1 ES8600650 A1 ES 8600650A1
Authority
ES
Spain
Prior art keywords
chosen
formula
acid
appropriate
microorganism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES533557A
Other languages
English (en)
Spanish (es)
Other versions
ES533557A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4255488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8600650(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of ES533557A0 publication Critical patent/ES533557A0/es
Publication of ES8600650A1 publication Critical patent/ES8600650A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES533557A 1983-06-22 1984-06-20 Procedimiento para la preparacion de derivados de leucina Expired ES8600650A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH341583 1983-06-22

Publications (2)

Publication Number Publication Date
ES533557A0 ES533557A0 (es) 1985-10-16
ES8600650A1 true ES8600650A1 (es) 1985-10-16

Family

ID=4255488

Family Applications (1)

Application Number Title Priority Date Filing Date
ES533557A Expired ES8600650A1 (es) 1983-06-22 1984-06-20 Procedimiento para la preparacion de derivados de leucina

Country Status (26)

Country Link
US (1) US4598089A (cg-RX-API-DMAC10.html)
EP (1) EP0129748B1 (cg-RX-API-DMAC10.html)
JP (1) JPS6013777A (cg-RX-API-DMAC10.html)
KR (1) KR920002314B1 (cg-RX-API-DMAC10.html)
AT (1) ATE30025T1 (cg-RX-API-DMAC10.html)
AU (1) AU572851B2 (cg-RX-API-DMAC10.html)
BG (1) BG60766B2 (cg-RX-API-DMAC10.html)
CA (1) CA1247547A (cg-RX-API-DMAC10.html)
DE (2) DE3466538D1 (cg-RX-API-DMAC10.html)
DK (1) DK160496C (cg-RX-API-DMAC10.html)
ES (1) ES8600650A1 (cg-RX-API-DMAC10.html)
FI (1) FI78694C (cg-RX-API-DMAC10.html)
GR (1) GR82120B (cg-RX-API-DMAC10.html)
HU (1) HU193579B (cg-RX-API-DMAC10.html)
IE (1) IE57761B1 (cg-RX-API-DMAC10.html)
IL (1) IL72122A (cg-RX-API-DMAC10.html)
LU (1) LU90302I2 (cg-RX-API-DMAC10.html)
LV (1) LV5747B4 (cg-RX-API-DMAC10.html)
MC (1) MC1602A1 (cg-RX-API-DMAC10.html)
MX (1) MX9203633A (cg-RX-API-DMAC10.html)
NL (1) NL980029I2 (cg-RX-API-DMAC10.html)
NO (2) NO159941C (cg-RX-API-DMAC10.html)
NZ (1) NZ208521A (cg-RX-API-DMAC10.html)
PH (1) PH19704A (cg-RX-API-DMAC10.html)
PT (1) PT78777B (cg-RX-API-DMAC10.html)
ZA (1) ZA844558B (cg-RX-API-DMAC10.html)

Families Citing this family (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA859574B (en) * 1984-12-21 1986-08-27 Hoffmann La Roche Process for the manufacture of oxetanones
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
JPH0618793Y2 (ja) * 1986-06-13 1994-05-18 パイオニア株式会社 作業台
US4806564A (en) * 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4816477A (en) * 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
US5017565A (en) * 1989-04-20 1991-05-21 Lange Iii Louis G Use of sulfated polysaccharides to inhibit pancreatic cholesterol esterase
US5484777A (en) * 1989-04-20 1996-01-16 Lange, Iii; Louis G. Pancreatic cholesterol esterase inhibitor
US5376640A (en) * 1989-12-25 1994-12-27 Nisshin Flour Milling Co., Ltd. Lipolytic enzyme inhibitors
JP2960947B2 (ja) * 1989-12-25 1999-10-12 日清製粉株式会社 脂質分解酵素阻害剤
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
TW381025B (en) * 1993-08-05 2000-02-01 Hoffmann La Roche Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
MY116591A (en) * 1996-04-26 2004-02-28 Hoffmann La Roche Process for the production of lipstatin and tetrahydrolipstatin
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
YU34199A (sh) * 1997-02-05 2002-08-12 F. Hoffmann-La Roche Ag. Primena inhibitora gastrointestinalne lipaze
US7344713B1 (en) * 1997-07-07 2008-03-18 Pimentel Julio L Decreased fat absorption with an anti-lipase antibody
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
RU2234917C2 (ru) * 1997-12-24 2004-08-27 Кнолль Акциенгезелльшафт Терапевтические средства
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6264937B1 (en) 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
DK1105123T3 (da) * 1998-08-14 2004-08-09 Hoffmann La Roche Farmaceutiske præparater indeholdende lipase-inhibitorer og chitosan
DK1105122T3 (da) 1998-08-14 2005-08-08 Hoffmann La Roche Pharmaceutical compositions containing lipase inhibitors
PT1140188E (pt) 1998-12-23 2003-10-31 Searle Llc Combinacoes de inibidores do transporte de acidos biliares do ileo e de inibidores da proteina de transferencia de esteres de colesterilo para doencas cardiovasculares.
AU776664B2 (en) 1998-12-23 2004-09-16 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
DE69908644T2 (de) 1998-12-23 2004-05-13 G.D. Searle Llc, Chicago Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
MXPA01006472A (es) 1998-12-23 2004-03-10 Searle Llc Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
WO2000038721A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
US6562860B1 (en) 1998-12-23 2003-05-13 G. D. Searle & Co. Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
ATE228118T1 (de) * 1999-01-29 2002-12-15 Hoffmann La Roche Reinigung von lipstatin
CA2379308A1 (en) * 1999-07-14 2001-01-25 Geltex Pharmaceuticals, Inc. Fat-binding polymers, optionally combined with lipase inhibitors
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
HK1052183A1 (zh) 2000-03-10 2003-09-05 Pharmacia Corporation 制造tetrahydrobenzothiepines的方法
EP1142572A1 (de) * 2000-04-04 2001-10-10 Volker Dr. Helmstädter Oxetanon-enthaltende Präparate zur Behandlung von Darmerkrankungen
DE10021618A1 (de) * 2000-05-04 2001-11-15 Volker Helmstaedter Präparat für Darmerkrankungen und dessen Verwendung
JP4149803B2 (ja) * 2000-06-27 2008-09-17 エフ．ホフマン−ラ ロシュ アーゲー 組成物の調製方法
CN1261094C (zh) * 2000-07-28 2006-06-28 霍夫曼-拉罗奇有限公司 脂肪酶抑制剂的新用途
EP1307264B1 (en) * 2000-07-28 2004-10-20 F. Hoffmann-La Roche Ag New pharmaceutical composition
DE60133470T2 (de) * 2000-08-09 2009-05-07 F. Hoffmann-La Roche Ag Lipase inhibitoren zur behandlung von dyspepsia
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
AR038762A1 (es) 2000-10-16 2005-01-26 Hoffmann La Roche Derivados de indolina, un proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion y el uso de dichos derivados para la fabricacion de un medicamento
GB0030710D0 (en) * 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
US6610685B2 (en) 2000-12-27 2003-08-26 Hoffmann-La Roche Inc. Fused indole derivatives
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
US20030072804A1 (en) * 2001-03-19 2003-04-17 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
US20030091610A1 (en) * 2001-03-19 2003-05-15 The Procter & Gamble Company Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
CA2446324A1 (en) * 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US7049345B2 (en) 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
RU2324696C2 (ru) 2001-08-30 2008-05-20 Ализайм Терапевтикс Лимитед Тиено-(1,3)-оксазин-4-оны, обладающие ингибирующей активностью по отношению к липазе
US6787558B2 (en) * 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
GB0125659D0 (en) * 2001-10-25 2001-12-19 Ssl Int Plc Spermicides
US6740663B2 (en) 2001-11-02 2004-05-25 G.D. Searle, Llc Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
AU2002359601A1 (en) 2001-12-04 2003-06-17 Biogal Gyogyszergyar Rt A fermentation process for lipstatin and method of extracting lipstatin from a fermentation broth
AU2002362061A1 (en) 2001-12-04 2003-06-17 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms
EA009368B1 (ru) 2001-12-20 2007-12-28 Оси Фармасьютикалз, Инк. Соединения-ингибиторы липазы поджелудочной железы, их синтез и применение
WO2003061604A2 (en) 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
JP4216196B2 (ja) * 2002-02-04 2009-01-28 エフ．ホフマン−ラ ロシュ アーゲー Ｎｐｙアンタゴニストとしてのキノリン誘導体
ATE373654T1 (de) * 2002-02-28 2007-10-15 Hoffmann La Roche Thiazolderivate als npy-rezeptorantagonisten
US7728153B2 (en) 2002-04-17 2010-06-01 The Burnham Institute For Medical Research Method for the asymmetric synthesis of beta-lactone compounds
AU2003226370A1 (en) * 2002-04-17 2003-11-03 The Burnham Institute Inhibition of fatty acid synthase by beta-lactones and other compounds for inhibition of cellular proliferation
MXPA04010371A (es) * 2002-04-26 2005-02-03 Hoffmann La Roche Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan.
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
BR0312461A (pt) * 2002-07-05 2005-04-26 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e métodos para tratamento e profilaxia
AU2003253364B2 (en) * 2002-08-07 2007-06-07 F. Hoffmann-La Roche Ag Thiazole derivatives
ES2275105T3 (es) * 2002-09-12 2007-06-01 F. Hoffmann-La Roche Ag Compuestos de acido 1-h-indol-5-propionico n-sustituidos como agonistas ppar utiles para el tratamiento de diabetes.
PL377320A1 (pl) * 2002-11-25 2006-01-23 F. Hoffmann-La Roche Ag Pochodne indolilowe
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20040178058A1 (en) * 2003-03-10 2004-09-16 Hsueh-Chung Chen Electro-chemical deposition apparatus and method of preventing cavities in an ECD copper film
EP1457206A1 (en) * 2003-03-13 2004-09-15 Fournier Laboratories Ireland Limited Combined use of a fibrate and orlistat for the treatment of obesity
CA2526730A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
WO2004113314A1 (en) * 2003-06-23 2004-12-29 Biocon Limited Novel boronate esters
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
AU2003253254A1 (en) * 2003-07-17 2005-02-04 Biocon Limited Preparation of tetrahydrolipstatin by hydrogenation of lipstatin, solvent extraction and purification
WO2005014592A1 (en) * 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag 2-amino-5-benzoylthiazole npy antagonists
EP1656374B1 (en) * 2003-08-12 2009-03-11 F. Hoffmann-La Roche Ag Thiazole derivatives as npy antagonists
US20050239859A2 (en) * 2003-09-03 2005-10-27 Solvay Pharmaceuticals Gmbh Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity
CN1902177A (zh) 2003-09-22 2007-01-24 万有制药株式会社 新哌啶衍生物
US20050143441A1 (en) * 2003-10-27 2005-06-30 Jochen Antel Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US20050124660A1 (en) * 2003-10-27 2005-06-09 Jochen Antel Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
AU2004312072B2 (en) * 2003-12-29 2011-06-23 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
PL209905B1 (pl) 2004-01-15 2011-11-30 Bringwell Internat Ab Preparat do leczenia otyłości i związanego z nią syndromu metabolicznego
EP1704861A4 (en) 2004-01-16 2009-11-25 Fuji Oil Co Ltd lipase
US7074822B2 (en) 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2005107777A1 (en) 2004-05-10 2005-11-17 Den Kgl. Veterinær- Og Landbohøjskole Flaxseeds for body weight management
JP2008508190A (ja) * 2004-07-19 2008-03-21 ノボ ノルディスク アクティーゼルスカブ 肥満または肥満に関連する疾患および障害の治療におけるカプサイシン受容体の活性の阻害
AU2005298692A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
ES2328384T3 (es) * 2004-11-23 2009-11-12 Warner-Lambert Company Llc Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia.
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
EP1888585B1 (en) * 2005-05-03 2011-06-29 F. Hoffmann-La Roche AG Tetracyclic azapyrazinoindolines as 5-ht2 ligands
CA2609388C (en) 2005-05-30 2013-08-06 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
EP1945635B1 (en) * 2005-08-18 2009-05-06 F.Hoffmann-La Roche Ag Thiazolyl piperidine derivatives useful as h3 receptor modulators
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd BICYCLIC AROMATIC SUBSTITUTED PYRIDONE DERIVATIVE
US7355055B2 (en) * 2005-09-08 2008-04-08 Reliance Life Sciences Pvt. Ltd. Compounds for treatment of lipase-mediated diseases
RU2008119687A (ru) 2005-10-21 2009-11-27 Новартис АГ (CH) Комбинации органических соединений
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
BRPI0618379A2 (pt) * 2005-11-08 2011-08-30 Ranbaxy Lab Ltd processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
WO2007055418A1 (ja) 2005-11-10 2007-05-18 Banyu Pharmaceutical Co., Ltd. アザ置換スピロ誘導体
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
BRPI0619268A2 (pt) * 2005-11-30 2011-09-20 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, uso dos compostos e método para o tratamento ou prevenção de obesidade e de diabetes do tipo ii em um ser humano ou animal
CN101316838B (zh) * 2005-11-30 2013-01-30 霍夫曼-拉罗奇有限公司 用作h3调节剂的1,1-二氧代-硫代吗啉基吲哚基甲酮衍生物
ES2342979T3 (es) * 2005-11-30 2010-07-20 F. Hoffmann-La Roche Ag Derivados de indol-2-carboxamida sustituidos en 5.
EP1960401B1 (en) * 2005-12-09 2009-11-11 F.Hoffmann-La Roche Ag Tricyclic amide derivatives useful for treating obesity
ATE449776T1 (de) * 2005-12-15 2009-12-15 Hoffmann La Roche Pyrroloä2,3-cüpyridinderivate
AU2006326067A1 (en) * 2005-12-16 2007-06-21 F. Hoffmann-La Roche Ag Pyrrolo [2 , 3-b] pyridine derivatives as H3 receptor modulators
SK22006A3 (sk) * 2006-01-03 2007-08-02 Biotika, A. S. Kmeň Streptomyces toxytricini produkujúci lipstatín a príprava lipstatínu s uvedeným kmeňom
US20080021092A1 (en) * 2006-01-06 2008-01-24 Deepak Murpani Stable pharmaceutical compositions of orlistat
EP1976840A1 (en) * 2006-01-13 2008-10-08 F.Hoffmann-La Roche Ag Cyclohexyl piperazinyl methanone derivatives and their use as histamine h3 receptor modulators
KR101047274B1 (ko) * 2006-01-23 2011-07-06 에프. 호프만-라 로슈 아게 Ｈ3 수용체 활성을 갖는 사이클로헥실 설폰아마이드 유도체
CL2007000667A1 (es) * 2006-03-14 2008-03-14 Ranbaxi Lab Ltd Composicion farmaceutica que comprende al acido 7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]pirrol-1-il]-3,5-dihidroxi-heptanoico o una sal y al menos un agente estabilizante; procedimiento de preparacion, util en e
KR101252635B1 (ko) 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
US7432255B2 (en) * 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2007137955A1 (en) * 2006-05-30 2007-12-06 F. Hoffmann-La Roche Ag Piperidinyl pyrimidine derivatives
JP2009543773A (ja) * 2006-07-14 2009-12-10 ランバクシー ラボラトリーズ リミテッド ＨＭＧ−ＣｏＡレダクターゼ阻害剤の多形体及びその使用
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
TW200831497A (en) * 2006-10-12 2008-08-01 Epix Delaware Inc Carboxamide compounds and their use
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
US20080200422A1 (en) * 2007-01-09 2008-08-21 Cavener Douglas R Methods for reduction of adipose tissue mass
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008236616A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent
WO2008124122A1 (en) * 2007-04-09 2008-10-16 Scidose, Llc Combinations of statins and anti-obesity agent and glitazones
US8158677B2 (en) 2007-06-01 2012-04-17 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
KR101504777B1 (ko) * 2007-06-06 2015-03-20 랜박시 래보러터리스 리미티드 오르리스타트의 제조 방법
US9066536B2 (en) * 2007-09-12 2015-06-30 University Of Copenhagen Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety
WO2009039157A2 (en) * 2007-09-17 2009-03-26 Dr. Reddy's Laboratories Ltd. Orlistat pharmaceutical formulations
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
US8298583B2 (en) * 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
BRPI0820701A2 (pt) 2007-12-11 2015-06-16 Cytopathfinder Inc Composto de carboxamida e seu uso como agonistas do receptor de quimiocina
US20090214682A1 (en) * 2008-02-22 2009-08-27 Heuer Marvin A Composition and methods for weight loss in a subject
EP2264026A4 (en) 2008-03-06 2012-03-28 Msd Kk ALKYLAMINOPYRIDINDERIVATE
EP2268822B1 (en) * 2008-03-26 2019-08-28 Biocon Limited Improved fermentation process for higher yield coefficient of lipase-inhibitor with respect to consumed fatty acid
WO2009119726A1 (ja) 2008-03-28 2009-10-01 萬有製薬株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2727914A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diaryl ketoxime derivative technical field
EP2141236A1 (en) * 2008-07-03 2010-01-06 KRKA, D.D., Novo Mesto Process for production of lipstatin and microorganisms therefore
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (ja) 2008-07-30 2010-02-04 萬有製薬株式会社 ５員－５員又は５員－６員縮環シクロアルキルアミン誘導体
JP2012504600A (ja) 2008-10-03 2012-02-23 シグマ・アリメントス・ソシエダ・アノニマ・デ・カピタル・バリアブレ 総コレステロールおよびｌｄｌコレステロールの制御ならびに／または体重減少ならびに／または熱産生を促進するための組成物
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
WO2010043592A1 (en) * 2008-10-15 2010-04-22 Revotar Biopharmaceuticals Ag Lipase inhibitors for use for the treatment of obesity
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
EP2395987A1 (en) 2009-02-12 2011-12-21 Coöperatieve Mirzorg U.A., Arnhem Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
US20100215635A1 (en) * 2009-02-23 2010-08-26 Zoltan Kiss Small molecules to induce weight loss or to reduce weight gain
US8993509B2 (en) 2009-03-31 2015-03-31 Robert Zimmerman Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
WO2010112569A1 (en) 2009-03-31 2010-10-07 Robert Zimmermann Modulation of adipose triglyceride lipase for prevention and treatment of cachexia, loss of weight and muscle atrophy and methods of screening therefor
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
RU2412713C2 (ru) * 2009-05-14 2011-02-27 Открытое Акционерное Общество Завод Экологической Техники И Экопитания "Диод" Фармацевтическая композиция, биологически активная добавка и способ уменьшения поглощения жира из пищи
WO2011028309A1 (en) 2009-09-04 2011-03-10 University Of Toledo PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY
SI2496583T1 (sl) 2009-11-02 2015-02-27 Pfizer Inc. Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
UA107369C2 (en) 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
US8524909B2 (en) 2010-02-02 2013-09-03 Hoffmann-La Roche Inc. Tetrahydro-pyran derivatives
RU2441654C2 (ru) * 2010-02-17 2012-02-10 Лабораториос Баго С.А. Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US8450350B2 (en) 2010-05-05 2013-05-28 Infinity Pharmaceuticals, Inc. Triazoles as inhibitors of fatty acid synthase
EP2566853B1 (en) 2010-05-05 2017-01-25 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US20130072519A1 (en) 2010-05-21 2013-03-21 Edward Lee Conn 2-phenyl benzoylamides
NO2575768T3 (cg-RX-API-DMAC10.html) 2010-05-24 2018-05-12
EP2392327A1 (en) 2010-06-04 2011-12-07 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Use of orlistat for the anti-parasitic treatment of a parasitic disease
PE20130781A1 (es) 2010-07-06 2013-07-20 Astrazeneca Ab Agentes terapeuticos 976
CN101885713B (zh) * 2010-07-19 2011-11-30 大邦(湖南)生物制药有限公司 一种毒三素链霉菌发酵液中分离提取利普司他汀的工艺
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN101948450B (zh) * 2010-10-13 2013-04-24 鲁南制药集团股份有限公司 一种生产制备奥利司他的方法
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
AU2011326871B2 (en) 2010-11-04 2015-02-12 Albireo Ab IBAT inhibitors for the treatment of liver diseases
WO2012064267A1 (en) 2010-11-08 2012-05-18 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
JP5728099B2 (ja) 2011-02-25 2015-06-03 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体
JP2014513923A (ja) 2011-03-04 2014-06-19 ファイザー・インク Ｅｄｎ３様ペプチドおよびその使用
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
CN102304105B (zh) * 2011-07-15 2013-07-10 鲁南新时代生物技术有限公司 一种制备高纯度奥利司他的方法
CN103030613B (zh) * 2011-09-29 2014-11-12 北大方正集团有限公司 一种利普司他汀的提纯方法
JP2013249293A (ja) * 2012-06-04 2013-12-12 Kao Corp リパーゼ活性阻害剤、抗真菌剤、及びフケ抑制剤
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
WO2014060445A1 (en) 2012-10-19 2014-04-24 Akzo Nobel Chemicals International B.V. Method for preparing high purity orlistat
CN102936234B (zh) * 2012-11-15 2015-04-01 江苏阿尔法药业有限公司 一种制备脂肪酶抑制剂奥利司他的方法
CN102993134B (zh) * 2012-12-31 2015-08-05 鲁南新时代生物技术有限公司 一种利普司他汀的提纯方法
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015026513A2 (pt) 2013-04-17 2017-07-25 Pfizer derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
CN113388007A (zh) 2013-06-05 2021-09-14 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX389591B (es) 2014-08-29 2025-03-20 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
EP3452023A1 (en) 2016-05-05 2019-03-13 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
BR112019007543A2 (pt) 2016-10-14 2019-07-02 Tes Pharma S R L inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
WO2020104456A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
FI3911648T3 (fi) 2019-01-18 2025-01-10 Astrazeneca Ab 6'-[[[(1s,3s)-3-[[5-(difluorometoksi)-2-pyrimidinyyli]amino]syklopentyyli]amino][1(2h),3'-bipyridin]-2-oni pcsk9:n estäjänä ja menetelmät sen käyttöön
NL2022615B1 (en) 2019-02-21 2020-08-31 Patrick Alexander Unger Pharmaceutical composition comprising tetrahydrocannabivarin for the prevention and treatment of overweight
US20230338387A1 (en) 2020-02-05 2023-10-26 Nof Corporation Agent For Treating Or Preventing Pancreatic Fistula
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608117B2 (ja) * 1977-02-08 1985-02-28 財団法人微生物化学研究会 新生理活性物質エステラスチンおよびその製造法
GB2023604B (en) * 1978-05-25 1982-07-28 Microbial Chem Res Found Physiologically active derivatives of esterastin and production thereof
JPS56128774A (en) * 1980-03-14 1981-10-08 Microbial Chem Res Found New physiologically active substance ebelactone and its preparation
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones

Also Published As

Publication number Publication date
HU193579B (en) 1987-10-28
NZ208521A (en) 1988-02-29
LV5747A4 (lv) 1996-10-20
ES533557A0 (es) 1985-10-16
GR82120B (cg-RX-API-DMAC10.html) 1984-12-13
AU572851B2 (en) 1988-05-19
IL72122A0 (en) 1984-10-31
ATE30025T1 (de) 1987-10-15
PH19704A (en) 1986-06-16
LV5747B4 (lv) 1996-12-20
ZA844558B (en) 1985-02-27
IE841566L (en) 1984-12-22
AU2947884A (en) 1985-01-03
FI842422A0 (fi) 1984-06-14
MC1602A1 (fr) 1985-05-09
DE3466538D1 (de) 1987-11-05
LU90302I2 (fr) 1998-12-21
KR920002314B1 (ko) 1992-03-21
DK160496C (da) 1991-08-26
PT78777A (en) 1984-07-01
KR850000530A (ko) 1985-02-27
HUT34545A (en) 1985-03-28
DK308584D0 (da) 1984-06-22
FI78694B (fi) 1989-05-31
EP0129748B1 (de) 1987-09-30
MX9203633A (es) 1992-07-01
NO842512L (no) 1984-12-27
NO2000003I1 (no) 2000-05-31
DK308584A (da) 1984-12-23
DE19875045I2 (de) 2000-01-20
IL72122A (en) 1987-07-31
NL980029I1 (nl) 1999-01-04
CA1247547A (en) 1988-12-28
DK160496B (da) 1991-03-18
IE57761B1 (en) 1993-03-24
EP0129748A1 (de) 1985-01-02
FI78694C (fi) 1989-09-11
NO159941C (no) 1989-02-22
NO159941B (no) 1988-11-14
US4598089A (en) 1986-07-01
JPS6013777A (ja) 1985-01-24
BG60766B2 (bg) 1996-02-29
NL980029I2 (nl) 1999-06-01
FI842422L (fi) 1984-12-23
JPH0516426B2 (cg-RX-API-DMAC10.html) 1993-03-04
PT78777B (en) 1986-09-15

Similar Documents

Publication Publication Date Title
ES8600650A1 (es) Procedimiento para la preparacion de derivados de leucina
ES457932A1 (es) Un procedimiento para la preparacion de nuevos compuestos antiparasitarios c-076, obtenidos en un caldo de fermenta- cion.
GB1453425A (en) 2-oxo-tetrahydropyran derivatives and fermentative process for producing the same
DK161091C (da) Svovlholdige antibiotiske forbindelser med antitumorvirkning, betegnet cl-1577a og cl-1577b, fremgangsmaade til fremstilling deraf, samt farmaceutiske praeparater indeholdende forbindelserne
JPS57115181A (en) Preparation of plant metabolite
KR890002214A (ko) 데만노실 테이코플라닌 유도체
ES8708017A1 (es) Un procedimiento para preparar teicoplanina a2 (t-a2)selectivamente enriquecida en cualquiera de sus componentes principales
BG41138A3 (bg) Метод за получаване на антибиотик а-21978
ES2135441T3 (es) Procedimiento para la preparacion de derivados de indolo-pirrolocarbazol.
ES8308357A1 (es) Un procedimiento para la produccion de l-lisina.
KR900003206A (ko) 항생물질 머사시딘, 이의 제조방법 및 약제로서의 이의 용도
ES553603A0 (es) Un procedimiento para la preparacion del complejo antibiotico a-21978 c o sus factores c0,c1,c2,c3,c4, 0 c5.
DZ658A1 (fr) Antibiotiques produits par kibdelosporagium aridumet leur préparation.
ES478874A1 (es) Procedimiento de preparar 3-0(beta -d-glucuronopiranosil)- soja-sapogenol b.
KR890005139A (ko) 테이코플라닌 유사 유도체
GB1500965A (en) Cyclic ether antibiotics
ES463206A1 (es) Un metodo para preparar maytansinol, maytanacina o propiona-to de maytansinol.
RU2001116104A (ru) Ванкорезмицин, способ его получения и его использование в качестве лекарственного средства
GB1525977A (en) Aminoglycoside antibiotic complex
GB1185123A (en) Fermentation Processes Utilizing Gaseous Hydrocarbons
MX167931B (es) Procedimiento para la produccion de 19-epi-dianemicina
ES475179A1 (es) Un metodo mejorado para producir antibiotico c-15003 p-4.
ES2056967T3 (es) Ws-9326a, ws-9326b y sus derivados.
ES8502729A1 (es) "un procedimiento para producir el complejo antibiotico m 9226"
ATE18233T1 (de) De-(mycinosyloxy)-tylosin-derivate.

Legal Events

Date Code Title Description
SPCF Request for supplementary protection certificate filed

Free format text: ORLISTAT (XENICAL)

Spc suppl protection certif: C9800034

Filing date: 19980910

SPCG Supplementary protection certificate granted

Free format text: ORLISTAT (XENICAL)

Spc suppl protection certif: C9800034

Filing date: 19980910

Expiry date: 20100423

Effective date: 20020122

SPCG Supplementary protection certificate granted

Free format text: ORLISTAT (XENICAL)

Spc suppl protection certif: C9800034

Filing date: 19980910

Expiry date: 20100423

Effective date: 20020122

FD1A Patent lapsed

Effective date: 20050425